Gilead, Vertex initiated as new big biotech buys at Citi
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
Gilead Sciences (GILD) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Hosted on MSN1d
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
Gilead reports results from pivotal Phase 3 PURPOSE 2 trial
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
Gilead Sciences: Approaching Overvalued
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Business Wire6d
Gilead Sciences to Present at Upcoming Investor Engagements
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...